ANAB (AnaptysBio, Inc.) Stock Market Reviews

crown

search

Read and share opinions on ANAB (AnaptysBio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

ANAB

AnaptysBio, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
Nov 4, 2025
Anaptys Announces Participation in November Investor Conferences
Nov 4, 2025
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades
Nov 1, 2025
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Oct 28, 2025
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
Oct 13, 2025
AnaptysBio's Split Announcement Seems 'Awkward' Amid Clinical Activities, Truist Securities Says
Sep 30, 2025
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
Sep 29, 2025
Anaptys Announces Participation in September Investor Conferences
Aug 27, 2025
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Aug 6, 2025
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
May 27, 2025

Reviews